- Home
- DVAX vs BASE Comparison
DVAX vs BASE Comparison
Compare DVAX & BASE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- BASE
- Stock Information
- Founded
- DVAX 1996
- BASE 2011
- Country
- DVAX United States
- BASE United States
- Employees
- DVAX N/A
- BASE N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- BASE EDP Services
- Sector
- DVAX Health Care
- BASE Technology
- Exchange
- DVAX Nasdaq
- BASE Nasdaq
- Market Cap
- DVAX 1.3B
- BASE 1.3B
- IPO Year
- DVAX 2004
- BASE 2021
- Fundamental
- Price
- DVAX $9.70
- BASE N/A
- Analyst Decision
- DVAX Buy
- BASE Hold
- Analyst Count
- DVAX 4
- BASE 15
- Target Price
- DVAX $26.50
- BASE $23.29
- AVG Volume (30 Days)
- DVAX 1.9M
- BASE 728.5K
- Earning Date
- DVAX 11-06-2025
- BASE 09-03-2025
- Dividend Yield
- DVAX N/A
- BASE N/A
- EPS Growth
- DVAX N/A
- BASE N/A
- EPS
- DVAX N/A
- BASE N/A
- Revenue
- DVAX $316,268,000.00
- BASE $220,639,000.00
- Revenue This Year
- DVAX $23.23
- BASE $12.14
- Revenue Next Year
- DVAX $16.57
- BASE $14.38
- P/E Ratio
- DVAX N/A
- BASE N/A
- Revenue Growth
- DVAX 26.66
- BASE 10.97
- 52 Week Low
- DVAX $9.20
- BASE $12.78
- 52 Week High
- DVAX $14.63
- BASE $25.16
- Technical
- Relative Strength Index (RSI)
- DVAX 41.54
- BASE 62.34
- Support Level
- DVAX $9.20
- BASE $24.40
- Resistance Level
- DVAX $9.94
- BASE $24.50
- Average True Range (ATR)
- DVAX 0.30
- BASE 0.04
- MACD
- DVAX -0.05
- BASE -0.03
- Stochastic Oscillator
- DVAX 40.65
- BASE 36.67
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About BASE Couchbase Inc.
Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.